Nanoformulation of the K-Ras(G12D)-inhibitory peptide KS-58 suppresses colorectal and pancreatic cancer-derived tumors

Cancer nanomedicine: progress, challenges and opportunities

Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.108 · Cited by 5,873 · see citing works

Renal clearance of quantum dots

Soo Choi, H., Liu, W., Misra, P., Tanaka, E., Zimmer, J. P., Itty Ipe, B., Bawendi, M. G., & Frangioni, J. V. (2007) · Nature Biotechnology · doi:10.1038/nbt1340 · Cited by 4,476 · see citing works

Animal research: Reporting <i>in vivo</i> experiments: The ARRIVE guidelines

Kilkenny, C., Browne, W., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00872.x · Cited by 3,625 · see citing works

Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation

Skoulidis, F., Li, B. T., Dy, G. K., Price, T. J., Falchook, G. S., Wolf, J., Italiano, A., Schuler, M., Borghaei, H., Barlesi, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103695 · Cited by 1,849 · see citing works

Cremophor EL

Gelderblom, H. A. J., Verweij, J., Nooter, K., & Sparreboom, A. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00171-x · Cited by 1,659 · see citing works

Implementing guidelines on reporting research using animals ( <scp>ARRIVE</scp> etc.): new requirements for publication in <scp>BJP</scp>

McGrath, J. C., & Lilley, E. (2015) · British Journal of Pharmacology · doi:10.1111/bph.12955 · Cited by 1,321 · see citing works

Nanodrug Delivery: Is the Enhanced Permeability and Retention Effect Sufficient for Curing Cancer?

Nakamura, Y., Mochida, A., Choyke, P. L., & Kobayashi, H. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00437 · Cited by 1,107 · see citing works

RAS-targeted therapies: is the undruggable drugged?

Moore, A. R., Rosenberg, S. C., McCormick, F., & Malek, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0068-6 · Cited by 1,103 · see citing works

Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS ^G12D Inhibitor

Wang, X., Allen, S., Blake, J. F., Bowcut, V., Briere, D. M., Calinisan, A., Dahlke, J. R., Fell, J. B., Fischer, J. P., Gunn, R. J., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01688 · Cited by 769 · see citing works

Elimination Pathways of Nanoparticles

Poon, W., Zhang, Y.-N., Ouyang, B., Kingston, B. R., Wu, J. L. Y., Wilhelm, S., & Chan, W. C. W. (2019) · ACS Nano · doi:10.1021/acsnano.9b01383 · Cited by 578 · see citing works

Size‐Dependent EPR Effect of Polymeric Nanoparticles on Tumor Targeting

Kang, H., Rho, S., Stiles, W. R., Hu, S., Baek, Y., Hwang, D. W., Kashiwagi, S., Kim, M. S., & Choi, H. S. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201901223 · Cited by 483 · see citing works

Emerging strategies to target RAS signaling in human cancer therapy

Chen, K., Zhang, Y., Qian, L. M., & Wang, P. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01127-w · Cited by 231 · see citing works

Targeting KRAS mutant cancers: from druggable therapy to drug resistance

Zhu, C., Guan, X., Zhang, X., Luan, X., Song, Z., Cheng, X., Zhang, W., & Qin, J.-J. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01629-2 · Cited by 231 · see citing works

Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer

Molina-Arcas, M., Moore, C., Rana, S., van Maldegem, F., Mugarza, E., Romero-Clavijo, P., Herbert, E., Horswell, S., Li, L.-S., Janes, M. R., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw7999 · Cited by 203 · see citing works

Acylated heptapeptide binds albumin with high affinity and application as tag furnishes long-acting peptides

Zorzi, A., Middendorp, S. J., Wilbs, J., Deyle, K., & Heinis, C. (2017) · Nature Communications · doi:10.1038/ncomms16092 · Cited by 141 · see citing works

Nanocarriers for pancreatic cancer imaging, treatments, and immunotherapies

Liu, L., Kshirsagar, P., Gautam, S. K., Gulati, M., Wafa, E. I., Christiansen, J. C., White, B. M., Mallapragada, S. K., Wannemuehler, M. J., Sushil Kumar, K., et al. (2022) · Theranostics · doi:10.7150/thno.64805 · Cited by 124 · see citing works

K-Ras(G12D)-selective inhibitory peptides generated by random peptide T7 phage display technology

Sakamoto, K., Kamada, Y., Sameshima, T., Yaguchi, M., Niida, A., Sasaki, S., Miwa, M., Ohkubo, S., Sakamoto, J.-I., Kamaura, M., et al. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.01.147 · Cited by 118 · see citing works

Guide for the Care and Use of Laboratory Animals

National Research Council (1996) · National Academies Press eBooks · doi:10.17226/5140 · Cited by 109 · see citing works

Expanding the scope of electrophiles capable of targeting K-Ras oncogenes

McGregor, L. M., Jenkins, M. L., Kerwin, C., Burke, J. E., & Shokat, K. M. (2017) · Biochemistry · doi:10.1021/acs.biochem.7b00271 · Cited by 97 · see citing works

Generation of KS-58 as the first K-Ras(G12D)-inhibitory peptide presenting anti-cancer activity in vivo

Sakamoto, K., Masutani, T., & Hirokawa, T. (2020) · Scientific Reports · doi:10.1038/s41598-020-78712-5 · Cited by 85 · see citing works

Crystal Structure of a Human K-Ras G12D Mutant in Complex with GDP and the Cyclic Inhibitory Peptide KRpep-2d

Sogabe, S., Kamada, Y., Miwa, M., Niida, A., Sameshima, T., Kamaura, M., Yonemori, K., Sasaki, S., Sakamoto, J.-I., & Sakamoto, K. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00128 · Cited by 83 · see citing works

Pharmacokinetics, Metabolism, Distribution and Permeability of Nanomedicine

Ravindran, S., Suthar, J. K., Rokade, R., Deshpande, P., Singh, P., Pratinidhi, A., Khambadkhar, R., & Utekar, S. (2018) · Current Drug Metabolism · doi:10.2174/1389200219666180305154119 · Cited by 83 · see citing works

Submicron Size Particles of a Murine Monoclonal Antibody Are More Immunogenic Than Soluble Oligomers or Micron Size Particles Upon Subcutaneous Administration in Mice

Kijanka, G., Bee, J. S., Korman, S. A., Wu, Y., Roskos, L. K., Schenerman, M. A., Slütter, B., & Jiskoot, W. (2018) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2018.06.029 · Cited by 75 · see citing works

Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies

Désage, A.-L., Léonce, C., Swalduz, A., & Ortiz‐Cuaran, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.796832 · Cited by 60 · see citing works

Membrane Trafficking and Subcellular Drug Targeting Pathways

Kumar, A., Ahmad, A., Vyawahare, A., & Khan, R. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00629 · Cited by 57 · see citing works

Nanomedicine in Pancreatic Cancer: Current Status and Future Opportunities for Overcoming Therapy Resistance

Greene, M. K., Johnston, M. C., & Scott, C. J. (2021) · Cancers · doi:10.3390/cancers13246175 · Cited by 56 · see citing works

Novel coumarin modified GLP ‐1 derivatives with enhanced plasma stability and prolonged in vivo glucose‐lowering ability

Han, J. D. J., Sun, L., Huang, X., Li, Z., Zhang, C., Qian, H., & Huang, W. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12843 · Cited by 51 · see citing works

Size-Dependent Phagocytic Uptake and Immunogenicity of Gliadin Nanoparticles

Alqahtani, M. S., Syed, R., & Alshehri, M. (2020) · Polymers · doi:10.3390/polym12112576 · Cited by 46 · see citing works

Investigation of the structural requirements of K-Ras(G12D) selective inhibitory peptide KRpep-2d using alanine scans and cysteine bridging

Niida, A., Sasaki, S., Yonemori, K., Sameshima, T., Yaguchi, M., Asami, T., Sakamoto, K., & Kamaura, M. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.04.063 · Cited by 41 · see citing works

Drugging the Next Undruggable KRAS Allele-Gly12Asp

Zheng, Q., Peacock, D. M., & Shokat, K. M. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00099 · Cited by 41 · see citing works

Pharmacokinetics and pharmacodynamics of a polyethylene glycol (PEG)-conjugated GLP-receptor agonist once weekly in Chinese patients with type 2 diabetes

Yang, G.-R., Zhao, X.-L., Jin, F., Shi, L.-H., & Yang, J.-K. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.386 · Cited by 29 · see citing works

The K-Ras(G12D)-inhibitory peptide KS-58 suppresses growth of murine CT26 colorectal cancer cell-derived tumors

Sakamoto, K., Lin, B., Nunomura, K., Izawa, T., & Nakagawa, S. (2022) · Scientific Reports · doi:10.1038/s41598-022-12401-3 · Cited by 21 · see citing works

PEGylated neuromedin U-8 shows long-lasting anorectic activity and anti-obesity effect in mice by peripheral administration

Masuda, Y., Kumano, S., Noguchi, J., Sakamoto, K., Inooka, H., & Ohtaki, T. (2017) · Peptides · doi:10.1016/j.peptides.2017.04.001 · Cited by 16 · see citing works

The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives

Takeda, M., Yoshida, S., Inoue, T., Sekido, Y., Hata, T., Hamabe, A., Ogino, T., Miyoshi, N., Uemura, M., Yamamoto, H., et al. (2025) · Cancers · doi:10.3390/cancers17030428 · Cited by 82 · see citing works

Tackling Undruggable Targets with Designer Peptidomimetics and Synthetic Biologics

Swenson, C., Mandava, G., Thomas, D. M., & Moellering, R. E. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00423 · Cited by 48 · see citing works

Advancements in Systemic Therapy for Pancreatic Cancer

Brown, T. J., Reiss, K. A., & O’Hara, M. H. (2023) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_397082 · Cited by 20 · see citing works

Harnessing epigenetic inhibitors: A promising approach for overcoming challenges in pancreatic ductal adenocarcinoma treatment

Maietta, I., González‐Fernández, Á., & Simón‐Vázquez, R. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115638 · Cited by 13 · see citing works

The VIPR2-selective antagonist KS-133 changes macrophage polarization and exerts potent anti-tumor effects as a single agent and in combination with an anti-PD-1 antibody

Sakamoto, K., Kittikulsuth, W., Miyako, E., Akumwami, S., Ishimura, R., Nakagawa, S., Ago, Y., & Nishiyama, A. (2023) · PLoS ONE · doi:10.1371/journal.pone.0286651 · Cited by 11 · see citing works

The Nanotechnology-Based Approaches against Kirsten Rat Sarcoma-Mutated Cancers

Andrade, F., German-Cortés, J., Montero, S., Carcavilla, P., Baranda-Martínez-Abascal, D., Moltó‐Abad, M., Seras‐Franzoso, J., Díaz‐Riascos, Z. V., Rafael, D. F. D. S., & Abasolo, I. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15061686 · Cited by 9 · see citing works

Discovery and Evaluation of C6-Substituted Pyrazolopyrimidine-Based Bisphosphonate Inhibitors of the Human Geranylgeranyl Pyrophosphate Synthase and Evaluation of Their Antitumor Efficacy in Multiple Myeloma, Pancreatic Ductal Adenocarcinoma, and Colorectal Cancer

Boutin, R., Lee, H., Guan, T. L., Nguyen, T. T., Huang, X. F., Waller, D. D., Lu, J., Chio, I. I. C., Michel, R. P., Sébag, M., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01271 · Cited by 8 · see citing works

Enhanced Killing of Colon Cancer Cells by Mesoporous Silica Nanoparticles Loaded with Ellagic Acid

AbouAitah, K., Nassrallah, A., Soliman, A. A. F., Świderska‐Środa, A., Tadeusz Chudoba, A., Smalc‐Koziorowska, J., Kim, B. S., & Łojkowski, W. (2025) · Nanomaterials · doi:10.3390/nano15201547 · Cited by 7 · see citing works

Artificial intelligence assisted design of nanomedicines for colorectal cancer diagnosis and therapy: Advances, challenges, and future directions

Dhanapal, Y., Sridhar, D., Khute, S., Subash, P., & Thangadurai, A. (2026) · Intelligent Pharmacy · doi:10.1016/j.ipha.2026.01.001 · Cited by 4 · see citing works

Post-Translational Modifications: Key “Regulators” of Pancreatic Cancer Malignant Phenotype—Advances in Mechanisms and Targeted Therapies

Shi, Y., Qin, R., & Li, Y. (2025) · Biomedicines · doi:10.3390/biomedicines13123013 · Cited by 2 · see citing works

Malolactone strikes: K-Ras-G12D's Achilles' heel

Adamopoulos, C., Papavassiliou, K. A., & Papavassiliou, A. G. (2024) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.04.001 · Cited by 2 · see citing works

Precision peptide disruptors: The next generation of targeted therapeutics in oncology

O'Gorman, B., Cooke, S. F., & Blair, C. M. (2025) · Cellular Signalling · doi:10.1016/j.cellsig.2025.111783 · Cited by 2 · see citing works

The Effect of Chenopodium quinoa Willd. Extract on DMH‐Induced Colorectal Cancer and Hepatic Oxidative Stress Through Monitoring PI3K/Akt/mTOR Pathway

Koumayha, A., Borjac, J., & Matar, A. (2026) · Advances in Pharmacological and Pharmaceutical Sciences · doi:10.1155/adpp/5552606

BindingDB Entry 50020541: Discovery and Evaluation of C6-Substituted Pyrazolopyrimidine-Based Bisphosphonate Inhibitors of the Human Geranylgeranyl Pyrophosphate Synthase and Evaluation of Their Antitumor Efficacy in Multiple Myeloma, Pancreatic Ductal Adenocarcinoma, and Colorectal Cancer.

BindingDB (2024) · UC San Diego · doi:10.7270/q22n56qk

An insights into impact of nanocarriers bearing phytopharmaceuticals in the management of cancer

Kaushik, R., Sharma, V., Kumar, S., Verma, K. K., & Gaur, P. K. (2026) · Journal of Biomaterials Science Polymer Edition · doi:10.1080/09205063.2026.2742611

The K-Ras(G12D)-inhibitory peptide KS-58 suppresses growth of murine CT26 colorectal cancer cell-derived tumors

Sakamoto, K., Lin, B., Nunomura, K., Izawa, T., & Nakagawa, S. (2022) · Scientific Reports · doi:10.1038/s41598-022-12401-3 · Cited by 21 · see citing works

Generation of KS-58 as the first K-Ras(G12D)-inhibitory peptide presenting anti-cancer activity in vivo

Sakamoto, K., Masutani, T., & Hirokawa, T. (2020) · Scientific Reports · doi:10.1038/s41598-020-78712-5 · Cited by 85 · see citing works

Precision delivery of RAS-inhibiting siRNA to KRAS driven cancer via peptide-based nanoparticles

Strand, M. S., Krasnick, B. A., Pan, H., Zhang, X., Bi, Y., Brooks, C., Wetzel, C., Sankpal, N., Fleming, T., Goedegebuure, S. P., et al. (2019) · Oncotarget · doi:10.18632/oncotarget.27109 · Cited by 74 · see citing works

Abstract 5978: SPR2015, a highly potent and selective KRAS G12D (on) inhibitor, exhibits favorable pharmacokinetic behavior and significant anti-tumor efficacy against colorectal cancer as monotherapy in preclinical models

Qian, Y. H., Zhang, Z., Fu, Z., Zhou, K., Dai, M., Liu, S., Zhang, Y., & Hu, T. (2026) · Cancer Research · doi:10.1158/1538-7445.am2026-5978

Targeted nanodelivery of siRNA against KRAS G12D inhibits pancreatic cancer

Huang, R., Du, H., Cheng, L., Zhang, P., Meng, F., & Zhong, Z. (2023) · Acta Biomaterialia · doi:10.1016/j.actbio.2023.07.008 · Cited by 34 · see citing works